Esperion Therapeutics

Esperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Esperion Therapeutics reports robust Q4 earnings, eyes global expansion

Esperion Therapeutics delivered strong financial results in Q4 2022, driven by successful formulary additions and international partner growth.
The company faces challenges in increasing brand awareness and effectively positioning bempedoic acid post statins, requiring strategic marketing and market access initiatives.
Opportunities lie in leveraging upcoming trial results for label expansion, enhancing brand visibility, and capitalizing on international growth through partnerships.

Esperion Therapeutics excels in Q1 2023, poised for market opportunities

Esperion Therapeutics delivered robust Q1 results with revenue growth and positive market reactions to its studies. While facing legal challenges and operational discussions, the company is well-positioned to leverage opportunities in the market through its strong partnerships and financial stability.

Esperion Therapeutics excels in Q2 earnings, eyes label expansion opportunities

Esperion Therapeutics delivered strong financial performance in Q2 2023, driven by revenue growth, cost management, and strategic partnerships.
While facing challenges in managing expenses, the company is well-positioned to capitalize on market opportunities post-label expansion approvals.
With a solid cash position, ongoing operational efficiency efforts, and a focus on growth initiatives, Esperion is poised for continued success.
The company's commitment to innovation and patient outcomes bodes well for its future growth trajectory and market competitiveness.

Esperion Therapeutics excels in Q3 earnings amidst regulatory hurdles

Esperion Therapeutics delivered strong financial results in Q3 2023, driven by revenue growth and strategic collaborations, despite facing regulatory and litigation challenges.
The company's focus on expanding market presence through FDA approvals and international expansion presents promising growth avenues for future success.
With a solid financial position and ongoing initiatives to drive prescription growth, Esperion is poised to capitalize on market opportunities and navigate challenges effectively.

Esperion Therapeutics reports robust Q4 earnings and eyes market expansion

Esperion Therapeutics delivered strong financial performance in Q4 2023, showcasing significant revenue growth and strategic advancements.
While facing challenges in managing expenses and executing growth strategies, the company is well-positioned to capitalize on market opportunities and drive future expansion.
With a clear roadmap for expense management and a focus on product reach and market expansion, Esperion is poised for continued growth and value creation for stakeholders.
The settlement agreement and label expansion approvals provide a solid foundation for Esperion to leverage opportunities, overcome challenges, and drive sustainable growth.

Esperion Therapeutics posts robust Q1 results amid FDA label wins

Esperion Therapeutics delivered strong financial performance in Q1 2024, driven by revenue growth and FDA label expansions.
The company faces challenges in maintaining prescription growth and navigating payer dynamics post-label update.
Strategic initiatives and market opportunities present avenues for Esperion to capitalize on its recent successes and drive future growth.

Esperion Therapeutics reports robust Q2 revenue growth and global expansion

Esperion Therapeutics delivered strong financial performance in Q2 2024, driven by revenue growth and successful market expansion efforts.
While facing challenges such as debt extinguishment losses and high operating expenses, the company capitalized on opportunities for international growth and product marketability.
By leveraging strengths in expanded product labels and improved market access, Esperion is poised to navigate challenges and capitalize on growth opportunities in the pharmaceutical sector.

Esperion Therapeutics reports robust Q3 performance and eyes global expansion

Esperion Therapeutics delivered strong financial performance in Q3 2024, driven by revenue growth and strategic initiatives to expand market access and product offerings.
While challenges in achieving profitability persist, the company's focus on innovation, global expansion, and operational efficiency underscores its long-term growth potential.
By leveraging strengths in collaboration, research, and market differentiation, Esperion is poised to capitalize on opportunities for further international expansion and brand recognition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Esperion's Approval, And Other News: The Good, Bad, And Ugly Of Biopharma

Millions of patients who don't respond well enough to statins now have another affordable alternative.

FDA Approves Esperion Therapeutics' New Cholesterol Drug

– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in the U.S. in Nearly 20 Years for Indicated Patients ––  NEXLETOL Lowers LDL-Cholesterol with a First-in-Class Mechanism ––﻿   Fills an Unmet Need for Affordable Medicines for Millions of Patients with ASCVD or HeFH ––  NEXLETOL will be Commercially Available in the U.S. March 30, 2020  ––  Conference Call and Webcast on Monday, February 24 at 8:00 a.m. Eastern Time  –

Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine

Shares of Esperion Therapeutics crumbled Friday after the biotech company's cholesterol medicine gained Food and Drug Administration approval.

Biotech Stock Crumbles Despite Nabbing A Key Drug Approval

Esperion's Multiple Positives, And Other News: The Good, Bad And Ugly Of Biopharma

Esperion Therapeutics: Major Potential In Bempedoic Acid/Ezetimibe Combination For LDL-C Lowering

AbbVie

Agile Therapeutics

Amarin Corporation Plc

Eli Lilly

Merck

From a niche contraceptive to the world's top cancer treatment, the FDA has a number of interesting drugs its reviewing this month.

4 Dates Biotech Investors Should Circle in February

Esperion: Recent Pullback Offers Buying Opportunity Ahead Of February PDUFA Dates

The committee vote puts bempedoic acid on the path for likely approval by the European Medicines Agency.

European Advisory Group Backs Esperion's Cholesterol Drugs

–  Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet is an Oral, Once-Daily, Non-Statin Medicine that Lowers Bad Cholesterol with a First-in-Class Mechanism  –  –  Positive CHMP Opinion is Based on the Completed Pivotal Phase 3 Fixed Dose Combination Tablet LDL-Cholesterol Lowering Program  –  –  European Commission Decision on the Marketing Authorisation Application (MAA) Expected in April 2020; Daiichi Sankyo Europe to Lead EU Commercialization  –

Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia

–  Bempedoic Acid is an Oral, Once-Daily, Non-Statin Medicine that Lowers Bad Cholesterol with a First-in-Class Mechanism ––   Positive CHMP Opinion is Based on the Completed Pivotal Phase 3 LDL-Cholesterol Lowering Program ––   European Commission Decision on the Marketing Authorisation Application (MAA) Expected in April 2020; Daiichi Sankyo Europe to Lead EU Commercialization –

Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia

ANN ARBOR, Mich., Jan.  03, 2020  (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on January 2, 2020, the Compensation Committee of Esperion’s Board of Directors granted 358 restricted stock units (RSUs) to one new colleague under Esperion’s 2017 Inducement Equity Incentive Plan.

Esperion  Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Karyopharm Therapeutics

TG Therapeutics

Risk-taking investors flock to biotech for its constant flow of events that can spike or crush the stock prices of the companies developing the latest therapies.

Biotech's Most Volatile Binary Events for Q1

Aimmune Therapeutics

Epizyme

Horizon Pharma

With FDA approval deadlines approaching in 2020, these four drug developers could see substantial gains if they're successful.

4 Healthcare Stocks With FDA Approvals on the Horizon

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

Esperion Therapeutics (ESPR) Up 25.1% Since Last Earnings Report: Can It Continue?

Canopy Growth

Medicines

OrganiGram Holdings Inc.

Regeneron Pharmaceuticals

Marijuana beverages, edibles, and vapes are finally available in Canada, but marijuana stocks still have big obstacles to overcome.

Can Cannabis 2.0 Kickstart Marijuana Stocks?

Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize the launch.

Esperion's Promising Drugs Under Review, Funds a Concern

Esperion Therapeutics (ESPR) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Esperion Therapeutics (ESPR) Catches Eye: Stock Jumps 10%

ANN ARBOR, Mich., Nov.  17, 2019  (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analyses from four Phase 3 clinical studies of bempedoic acid were presented at the American Heart Association (AHA) Scientific Sessions in Philadelphia. Bempedoic acid is being developed as a convenient, once-daily, oral therapy for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C) added onto maximally tolerated statin therapy. Bempedoic acid and the bempedoic acid 180 mg + ezetimibe 10 mg fixed dose combination (FDC) tablets’ new drug applications (NDAs) are currently under regulatory review by the U.S. Food and Drug Administration (FDA) and the marketing authorisation applications (MAAs) are currently under centralized review by the European Medicines Agency (EMA).

Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions

 –  Study 2 Demonstrated that Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP –   –    Over 52- Weeks,  Overall Adverse Events in the Bempedoic Acid Treatment Arm were Comparable to Placebo –   – Bempedoic Acid is being developed as an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor that Reduces Cholesterol –   – Research by Anne C. Goldberg, MD, FACP, FAHA, FNLA published in the Journal of the American Medical Association –

Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results

Esperion Therapeutics (ESPR) reports mixed third-quarter results.

Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3

ANN ARBOR, Mich., Oct.  25, 2019  (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) announced that bempedoic acid was included in the “Top 10 Medical Innovations for 2020” at Cleveland Clinic’s 2019 Medical Innovation Summit on Wednesday, October 23rd. The Summit was comprised of a panel of physicians and scientists assembled to assess innovations and medicines that have the potential to enhance healthcare in the coming year. Bempedoic acid and the bempedoic acid / ezetimibe combination tablet are under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).

Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List

Esperion Therapeutics, owner of bempedoic acid (BA), aims to reduce LDL-C in statin-resistant/intolerant patients. BAs potential is massive considering the safety and efficacy data to date & size of market.

Esperion Therapeutics: Low Risk And Primed For Substantial Growth

Esperion Therapeutics (ESPR) Down 10.8% Since Last Earnings Report: Can It Rebound?

– 14,032 Patients are Now Fully Enrolled in the CLEAR Cardiovascular Outcomes Trial –  – Expect CLEAR Cardiovascular Outcomes Trial to Conclude in the Second Half of 2022 –

News for Esperion Therapeutics Stock (ESPR)